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http://dx.doi.org/10.1016/j.ccr.2014.04.016SUMMARYMutually exclusive activating mutations in the GNAQ and GNA11 oncogenes, encoding heterotrimeric Gaq
family members, have been identified in 83% and 6% of uveal and skin melanomas, respectively. How-
ever, the molecular events underlying these GNAQ-driven malignancies are not yet defined, thus limiting
the ability to develop cancer-targeted therapies. Here, we focused on the transcriptional coactivator YAP,
a critical component of the Hippo signaling pathway that controls organ size. We found that Gaq stimulates
YAP through a Trio-Rho/Rac signaling circuitry promoting actin polymerization, independently of phospho-
lipase Cb and the canonical Hippo pathway. Furthermore, we show that Gaq promotes the YAP-dependent
growth of uveal melanoma cells, thereby identifying YAP as a suitable therapeutic target in uveal melanoma, a
GNAQ/GNA11-initiated human malignancy.INTRODUCTION
Mutations in GNAQ and GNA11, encoding two members of the
Gaq family of heterotrimeric G protein a subunits, Gaq and
Ga11, respectively, occur in roughly 5% of all tumors sequenced
to date (O’Hayre et al., 2013). The majority of these mutations
affect residues Q209 and R183, which are required for Gaq gua-
nosine triphosphatase (GTPase) activity (Berman et al., 1996;
Van Raamsdonk et al., 2010). Thus, the most frequent mutations
observed in GNAQ and GNA11 render them GTPase defective
and constitutively active, leading to prolonged signaling. Of inter-
est, 83% of ocular melanomas harbor mutations in GNAQ orSignificance
Uveal melanoma is the most frequent ocular malignancy in ad
available. Recent findings revealed that activating mutations
of G protein a subunits, drive uveal melanoma oncogenesis. He
tivator YAP in human uveal melanoma cells andGNAQ-induced
YAP by acting on a Hippo-independent signaling network initia
uveal melanoma cell proliferation, thereby rendering it sensitiv
this cancer vulnerability can be exploited for the development o
malignancies.GNA11, where they are now considered to represent the driver
oncogenes (Van Raamsdonk et al., 2009; Van Raamsdonk
et al., 2010). This provides a clear example of a human malig-
nancy that is initiated by gain-of-function mutations in Gaq and
Ga11 proteins. Although less studied, GNAQ and GNA11 muta-
tions are also frequently found in leptomeningeal melanocyto-
mas (50%) and melanomas (25%) arising from the meninges
(Ku¨sters-Vandevelde et al., 2010), in most blue nevi of the skin
(83%), and in a subset (6%) of cutaneous melanomas (Van
Raamsdonk et al., 2009).
The best-known downstream signaling event initiated by Gaq
involves its ability to activate phospholipase C (PLC) b and theults, for which no effective systemic therapies are currently
in GNAQ and GNA11, encoding members of the Gaq family
re we report thatGNAQ stimulates the transcriptional coac-
cancer mousemodels. At themolecular level, Gaq activates
ted by actin polymerization. Ultimately, YAP is essential for
e to clinically relevant small-molecule YAP inhibitors. Hence,
f new precisionmolecular therapies forGNAQ-driven human
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Figure 1. Activating Mutations in Gaq—GaqQL—Induce YAP Nuclear Translocation and YAP-Dependent Transcription Activation through
Trio and Trio-Dependent Rho-GTPases
(A) Western blots show HA-Gaq and HA-GaqQL expression in HEK293 cells transfected with HA-Gaq or HA-GaqQL expression vectors (DNAs), using
endogenous glyceraldehyde 3-phosphate dehydrogenase as a loading control.
(B) Western blot shows YAP expression levels in the nuclear fraction; enrichment for lamin A/C and a tubulin served as nuclear and cytoplasmic markers
respectively.
(C and D) Immunofluorescence shows that transfected GaqQL induces YAP nuclear translocation, but not Gaq or mCherry. (C) Endogenous YAP (green) was
detected by immunofluorescence alongwith Hoechst for nuclear DNA (blue) and HA staining (violet) or mCherry (violet, as control). (D) Nuclear YAP in HA-positive
and mCherry-positive cells was quantified with ImageJ and represented as arbitrary units in the indicated cell populations (mean ± SEM, n = 50–100 cells).
(E) HEK293 cells were cotransfected with HA-Gaq or HA-GaqQL and Gal4-TEAD4, 5 3 UAS-Luc and Renilla-Luc DNAs followed by luciferase assay
(mean ± SEM, n = 3).
(legend continued on next page)
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GNAQ Drives Uveal Melanoma Growth through YAPconsequent increased hydrolysis of phosphatidylinositol 4,5-
bisphosphate to produce two second messengers: inositol
1,4,5-trisphosphate (IP3) and diacylglycerol (DAG) (Hubbard
and Hepler, 2006). IP3 raises cytoplasmic Ca
2+ levels, which
stimulates multiple calcium-regulated pathways and, together
with DAG, activates classic protein kinase C isoforms (Griner
and Kazanietz, 2007). However, the molecular events underlying
GNAQ-driven malignancies are not yet defined, thus limiting the
ability to develop novel anticancer-targeted therapies. Here, we
focused on the transcriptional coactivator YAP, a critical compo-
nent of the Hippo signaling pathway that controls organ size in
mammals (Pan, 2010; Ramos and Camargo, 2012; Sudol et al.,
1995; Zhao et al., 2010). YAP is active in most proliferating cells,
but upon reaching the appropriate cell density, signaling path-
ways initiated upon cell-cell contact and/or from the organ size-
sensing machinery lead to the activation of the Hippo kinase
cascade, resulting in the inhibitory activity of the mammalian
STE20-like protein kinases 1 and 2,which are themammalian ho-
mologs of Hippo in Drosophila melanogaster (Pan, 2010; Ramos
and Camargo, 2012; Zhao et al., 2010). This pathway converges
in the activation of a kinase known as large tumor suppressor
homolog 1 and 2 (LATS1 and LATS2 in humans), which phos-
phorylates YAP in serine 127, thereby targeting it for retention
and degradation in the cytosol and thus limiting its transcriptional
activity and resulting in growth inhibition (Camargo et al., 2007;
Dong et al., 2007; Pan, 2010; Ramos and Camargo, 2012).
In this study, we show that activating mutation of Gaq can
trigger YAP translocation into the nucleus and stimulate YAP-
dependent transcription and that this process is independent
from PLCb stimulation but requires the activation of a Gaq-regu-
lated guanine nucleotide exchange factor, Trio, and the subse-
quent activation of the small GTPases RhoA and Rac1 and their
associated signaling networks. In turn, this Gaq-Trio-Rho/Rac
signaling circuitry contributes to the YAP-dependent growth in
uveal melanoma, thus identifying suitable therapeutic targets
for uveal melanoma treatment.
RESULTS
YAP Activation Downstream of Oncogenic Activating
Mutants of Gaq—GaqQL—through RhoA and Rac1
To assess the expression and localization of the transcriptional
coactivator YAP in response to activating mutations in GNAQ,(F) HEK293 cells were transfected with HA-Gaq or HA-GaqQL, followed by PI tu
TEAD4, 5 3 UAS-Luc and Renilla-Luc DNAs, followed by PLCi treatment (1 hr) a
(G) Transfected HA-GaqQL or vector into shRNA-control, shRNA-Trio#1, and shR
panel) or by RhoA and Rac1 small GTPase activation assays (lower panels).
(H) HEK293 cells were cotransfected with siRNA Trio or control and HA-GaqQL
luciferase assay (mean ± SEM, n = 6).
(I) Western blot shows AU5-RhoAQL and AU5-Rac1QL expression in HEK293 ce
(J) Western blots show that both RhoAQL and Rac1QL can induce YAP accum
nuclear and cytoplasmic markers, respectively.
(K) HEK293 cells were cotransfected with AU5-RhoAQL or AU5-Rac1QL and Ga
(mean ± SEM, n = 6).
(L andM) Immunofluorescence assay and nuclear YAP quantification, using the pr
100 cells).
(N) HEK293 cells were cotransfected with siRNAs RhoA, Rac1, or control and H
followed by luciferase assay, as above (mean ± SEM, n = 6).
See also Figure S1.we transfected human embryonic kidney 293 (HEK293) cells
with human influenza hemagglutinin A epitope (HA)-tagged
GaqQL (Q209L), one of the most frequent GNAQ mutants in
uveal melanoma (O’Hayre et al., 2013), using empty vector and
wild-type Gaq as controls. Both tagged G protein a subunits
were expressed at similar levels (Figure 1A), but only the active
Gaq protein promoted the nuclear translocation of YAP, as
judged by its increased recovery in the nuclear fraction (Fig-
ure 1B) and by YAP immune detection in the nuclei of transfected
cells, which could be recognized by staining of the HA tag in the
background of untransfected cells (Figures 1C and 1D). GaqQL
also caused a remarkable increase in the luciferase activity of
a YAP reporter system driven by a TEAD4-Gal4 chimera, which
included the TEAD4 transactivation and YAP-binding domain,
and promoted the expression of endogenous YAP-regulated
genes, including CTGF and CYR61 (Figure 1E; Figure S1A
available online). These results, together with recently reported
biochemical studies (Yu et al., 2012), support that GNAQ-
activating signaling can lead to YAP nuclear translocation and
YAP-dependent activating gene transcription.
However, it is unclear which of the multiple Gaq-initiated path-
ways regulate YAP and how the interplay between YAP and other
GNAQ-initiated signaling pathways contributes to the trans-
duction of proliferative cues by this G protein and its coupled
receptors. Theactivation ofPLCb is oneof thebest-knowndown-
streamevents stimulated byGaq. Inhibition of PLCbby the use of
a small-molecule PLC inhibitor (PLCi) abolished the generation of
diffusible second messengers but did not affect the transcrip-
tional activation of YAP by Gaq (Figure 1F; Figure S1B), demon-
strating that activation of YAP may be independent of PLCb.
In a recent study, a genome-wide double-stranded RNA
screen in Drosophila cells revealed that Trio, a highly conserved
guanine nucleotide exchange factor, is essential for transducing
signals from Gaq to the AP1 transcription factors through the
activation of Rho-GTPases and their signaling circuitries (Vaque´
et al., 2013). These findings prompted us to investigate whether
Trio and its regulated Rho GTPases, RhoA and Rac1, participate
in the nuclear translocation and activation of YAP in response to
Gaq-activating mutations. Knockdown of Trio did not affect the
expression levels of GaqQL but abolished its ability to promote
the accumulation of activated RhoA and Rac1 (Figure 1G).
Knockdown of Trio also prevented the activation of the YAP tran-
scriptional activity caused by GaqQL (Figure 1H; Figure S1C).rnover assays (mean ± SEM, n = 6) (upper panel) or cotransfected with Gal4-
nd luciferase assay (mean ± SEM, n = 3) (lower panel).
NA–Trio#2 HEK293 cells, followed by the indicated western blot analysis (upper
or vector and Gal4-TEAD4, 5 3 UAS-Luc, and Renilla-Luc DNAs, followed by
lls transfected with the corresponding expression plasmids.
ulation in the nuclear fraction, using enrichment in lamin A/C and a tubulin as
l4-TEAD4, 5 3 UAS-Luc, and Renilla-Luc DNAs, followed by luciferase assays
ocedure described in (C) in the indicated transfected cells (mean ± SEM, n = 50–
A-GaqQL or vector and Gal4-TEAD4, 5 3 UAS-Luc, and Renilla-Luc DNAs,
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Figure 2. Conditional Expression of the GaqQL Promotes Melanoma or Skin Carcinoma Formation and YAP Activation In Vivo
(A) Dct-rtTA mice were bred with tet-H2BGFP transgenic mice to produce inducible Dct/H2BGFP double-transgenic mice, which express GFP exclusively in
melanocytes, when fed with doxycycline food (dox).
(B) Dct/H2BGFP mice show tight regulation GFP expression in skin melanocytes (green), using Hoeschst and phalloidin to stain nuclear DNA (blue) and cyto-
plasmic polymerized actin (red), respectively (as shown in Zaidi et al., 2011).
(C) Dct-rtTA/p16p19KO mice were bred with tet-HA-GaqQL/p16p19KO mice to produce inducible Dct/HA-GaqQL/p16p19KO mice, which expressed
HA-GaqQL exclusively in melanocytes, when fed with doxycycline food.
(legend continued on next page)
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GNAQ Drives Uveal Melanoma Growth through YAPHowever, although the activation of YAP by activated RhoA has
been recently reported (Yu et al., 2012), we observed that Rac1
can also stimulate the nuclear translocation of endogenous YAP
and its transactivating activity when expressed together with the
GAL4-TEAD4 reporter system (Figures 1I–1M). Interestingly,
knockdown of either of these two Rho-GTPases prevented the
transcriptional activation of YAP induced by GaqQL (Figure 1N;
Figures S1D and S1E). Thus, although the activated mutants of
either RhoA or Rac1 can activate YAP, the concomitant activa-
tion of both endogenous GTPases appears to be required for
the full stimulation of endogenous YAP when activated by onco-
genic forms of Gaq.
Conditional Expression of the GNAQ Oncogene
Promotes Melanoma Formation and YAP Activation
In Vivo
To investigate whether activated GNAQ can drive melanocyte
transformation in vivo, we generated a mouse model expressing
HA-GaqQL under the control of the tet-responsive elements (tet-
HA-GaqQL) and bred them with mice expressing the reverse
tetracycline-activated transactivator rtTA2, regulated by the
melanocyte-specific dopachrome tautomerase (Dct) gene pro-
moter (Dct-rtTA) (Zaidi et al., 2011). Initially, we used the nuclear
expression of a tet-driven H2B-GFP to document the targeted
expression to skin melanocytes by Dct-rtTA (Figures 2A and
2B), as previously reported (Zaidi et al., 2011). The tet-HA-
GaqQL and Dct-rtTA transgenic mice were also bred with mice
defective in p16Ink4a and p19Ink4b (p16p19KO) (Figure 2C), as
genetic and epigenetic inactivation of this tumor suppressive
pathway is a frequent event in uveal and cutaneous melanoma
(Castellano et al., 1997; van der Velden et al., 2001). This was
reflected by the methylation of the Ink4 (CDKN2) gene promoter
region in a representative panel of human melanoma cells lines
(Figure S2). Using this animal model system, we observed that
when HA-GaqQL was expressed in response to doxycycline
treatment in the p16p19KO background, more than 50% of the
mice developed cutaneous lesions of melanocytic origin ex-
pressing Dct (Figures 2D and 2E and data not shown). This is
aligned with the finding that hot-spot mutations in GNAQ and
its related GNA11 are mutated in 5% of all cutaneous mela-
nomas (O’Hayre et al., 2013; Van Raamsdonk et al., 2009), which
on the basis of our observations may represent a tumor-initiating
genetic event. In these lesions,most HA-GaqQL expressing cells
exhibit nuclear YAP, in contrast to normal tissues, in which con-
trol GFP expressing melanocytes exhibit cytoplasmic YAP (Fig-
ures 2F and 2G). Thus, mutated GNAQ can initiate melanocyte
transformation and tumor formation in mice when expressed in(D) Percentage of mice developing cutaneous lesions of melanocytic origin after
(E) Example of Dct/HA-GaqQL/p16p19KO mice developing lesions in the skin.
(F) Histology shows Dct/HA-GaqQL/p16p19KO mouse with cutaneous melanom
HA-GaqQL (green) positive cells display YAP (violet) nuclear translocation usin
H2BGFP mouse stained with GFP (green) instead of HA as control (left lower pa
(G) Quantification of percentage nuclear YAP-positive cells in GFP- or HA-positi
(H) K5-rtTAmice were bred with tet-O-HA-GaqQLmice to produce inducible K5/
(Vitale-Cross et al., 2004), when fed with doxycycline food.
(I) K5/HA-GaqQL mice developed rapid hair loss within days (left) and exhibited
(J) Histology showed that theseK5/HA-GaqQLmice developed skin carcinoma (m
HA-GaqQL mice exhibit YAP (green) nuclear translocation, using Hoechst to sta
See also Figure S2.a progenitor cell compartment and results in YAP nuclear local-
ization in vivo. As GNAQmutations have been identified in other
tumors, we expressed HA-GaqQL in the skin, including the hair
follicle stem cells, using a cytokeratin 5 (K5) rtTA diver (Figure 2H)
(Vitale-Cross et al., 2004). These mice developed rapid hair loss
within days and exhibited nuclear localization of YAP in epithe-
lial-derived hyperplastic cells in multiple tumor lesions (Figures
2I and 2J). Collectively, these results suggest that YAP activation
in tumors initiated by activating mutations of Gaq is likely a gen-
eral event, not restricted to melanocyte progenitor cells and their
derived tumors.
Trio and a Network of Rho-GTPases Mediate YAP
Activation in Uveal Melanoma Cells Harboring GNAQ
Mutations
We next examined the expression of YAP in human uveal mela-
noma lesions. Consistent with our experimental findings, we
observed that YAP accumulates in the nucleus in human uveal
melanoma lesions (Figures 3A and 3B). In contrast, normal
melanocytes do not express nuclear YAP in normal tissues.
This suggests that YAP may contribute to the oncogenic
pathway initiated by GNAQ- and GNA11-activating mutations
in human uveal melanomas. On the basis of these observations,
we next asked whether YAP is activated in uveal melanoma cells
expressing the GNAQ oncogene. Indeed, uveal melanoma cells
exhibited clear nuclear-localized YAP, which was insensitive to
PLC inhibition, similar to HEK293-expressing active Gaq, even
when PLCi was used to effectively block phosphatidylinositol hy-
drolysis (Figures 3C and 3D). The nuclear localization of YAPwas
abolished after GNAQ knockdown in uveal melanoma cell lines
(Figures 3E and 3F). Similarly, knockdown of Trio, RhoA, and
Rac1 prevented the nuclear accumulation of YAP in these cells
and diminished the expression of endogenous YAP-regulated
genes, CTGF and CYR61 (Figures 3E–3G). These findings sup-
port that in uveal melanoma cells harboring GNAQ mutations,
Gaq primarily signals through Trio to RhoA and Rac1 to promote
the nuclear localization and activation of YAP, independent of
PLC activation and its downstream regulated events.
Surprisingly, uveal melanoma cells displayed very high levels
of total and phosphorylated (serine 127) YAP. The latter likely
represents the YAP-inactive form upon phosphorylation by
LATS1 and LATS2, which are highly expressed in these cells,
similar to cutaneous melanoma cells expressing BRAF and
NRAS oncogenes, which served as controls. LATS1 was also
recognized by antibodies detecting its phosphorylated form
at the hydrophobic motif (T1079) and activation loop (S909)
both in uveal melanoma cells and in HEK293 cells expressingfeeding with doxycycline food.
a (upper right panel). Immunofluorescence assay of frozen tissues shows that
g Hoechst for DNA staining (blue) (right lower panel). Normal skin from Dct/
nel) shows cytoplasmic YAP.
ve cells (GFP+ and HA+, respectively).
HA-GaqQLmice, which express HA-GaqQL exclusively in basal epithelial cells
multiple tumor lesions on the skin (right).
iddle lower panel). Immunofluorescence assays in frozen tissues show thatK5/
in nuclear DNA (blue) (right lower panels).
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Figure 3. Trio and a Network of Rho-GTPases Mediate YAP Activation in Uveal Melanoma Cells Harboring GNAQ Mutations
(A) Immunofluorescence assays using frozen tissues from clinical uveal melanoma specimens (n = 6) showed HMB-45-positive cells (red) with nuclear YAP
(green), using Hoechst to stain nuclear DNA (blue), using as control HMB-45 staining to identify the resident melanocytes in normal tissues (n = 3).
(B) Quantification of percentage nuclear YAP-positive cells in melanosome-positive cells.
(C) PLCi inhibits the hydrolysis of PIs in OMIM1.3 uveal melanoma cells as judged by PI turnover assays.
(D) HEK293 cells transfected with GaqQL expression vectors and OMM1.3 uveal melanoma cells exhibited nuclear YAP by immunofluorescence (green), which
was insensitive to PLC inhibition, using Hoechst and phalloidin to stain nuclear DNA (blue) and cytoplasmic polymerized actin (red), respectively.
(E) Western blot analysis documents knockdown using siRNAs in two uveal melanoma cell lines.
(F) OMM1.3 uveal melanoma transfected with siRNA control show cells with YAP (green) nuclear staining, while cells transfected with the indicated siRNAs show
YAP mainly localized to the cytoplasm. Hoechst stains nuclear DNA (blue).
(G) siRNA knockdown of Gaq, Trio, RhoA, or Rac1 diminishes the expression of endogenous YAP-regulated genes (CTGF and CYR61) in OMM1.3 and OMM1.5
uveal melanoma cells (mean ± SEM, n = 3).
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GNAQ Drives Uveal Melanoma Growth through YAPGNAQ (Figure 4A).GNAQ expression in HEK293 cells resulted in
the accumulation of dephosphorylated YAP, reflected by the
faster migration of YAP in Phos-tag-containing gels, with only
dephosphorylated YAP accumulating in the nucleus (Figure 4B).
All uveal melanoma cells also accumulated dephosphorylated
YAP, although they still retained phospho-YAP (Figures 4A
and 4C). Together, these observations suggested that LATS1/
LATS2 may remain active in uveal melanoma cells and raised836 Cancer Cell 25, 831–845, June 16, 2014 ª2014 Elsevier Inc.the possibility that YAP activation by GNAQ may involve mech-
anisms in addition to those described resulting in Hippo pathway
inactivation and LATS1/2 inhibition (Yu et al., 2012).
To explore this possibility, we knocked down LATS1/2 in
HEK293 cells, which alone induced only a slight increase
in YAP transcriptional activity in confluent cells. Interestingly,
the GNAQ oncogene induced the transcriptional activation of
YAP even when the repressing signals converging on LATS1/2
Cancer Cell
GNAQ Drives Uveal Melanoma Growth through YAPwere suppressed by knockdown of both human LATS isoforms
(Figures 4D–4F), supporting that activation of YAP by GaqQL is
not solely dependent on the inhibition of the Hippo pathway.
Recently, a likely Hippo-independent pathway resulting in the
activation of YAP initiated by actin polymerization was described
in the context of cell mechanical sensing (Aragona et al., 2013;
Dupont et al., 2011; Halder et al., 2012). Aligned with the strong
activation of RhoA and Rac by GaqQL, uveal melanoma cells
exhibit high levels of phosphorylated cofilin (p-cofilin) (Figure 4G),
a downstream target of both of these GTPases (Figures 4H
and 4I). Accumulation of p-cofilin results in increased actin poly-
merization and the consequent increase in polymerized F-actin
and decrease in monomeric G-actin (Bernard, 2007; Pollard
and Cooper, 2009). Remarkably, YAP nuclear localization and
activity were repressed when blocking actin polymerization by
inhibiting ROCK, thereby limiting cofilin phosphorylation specif-
ically downstream of RhoA or by the direct inhibition of G-actin
assembly into F-actin by latrunculin-A (Lat.A) (Figures 4J–4M;
Figure S3). Together, these findings suggest that GNAQ may
stimulate YAP by promoting actin polymerization rather than
by solely inhibiting the canonical Hippo pathway.
A Hippo-Independent Pathway Regulated by Actin
Polymerization Contributes to YAP Activation in Uveal
Melanoma
We next explored the interplay between the Hippo pathway and
actin polymerization in YAP activation. Knockdown of LATS1/2
resulted in a remarkable increase in the expression of YAP-regu-
lated genes in uveal melanoma cells, further supporting that the
Hippo pathway remains active in these cells, restraining maximal
YAP activation (Figures 5A and 5B). Even when LATS1/2 was
knocked down, inhibition of actin polymerization decreased
YAP activity, both in uveal melanoma and GaqQL transfected
cells (Figures 5B–5D), suggesting that F-actin accumulation and
LATS inhibition may act in a coordinated fashion. Regarding the
former, how actin polymerization results in YAP stimulation is
complex and not fully understood (Aragona et al., 2013; Dupont
et al., 2011; Halder et al., 2012; Johnson and Halder, 2014).
Recent studies suggest that YAPmay formmanymultimeric pro-
tein complexes using itsWWdomains, a leucine zipper and PDZ-
binding motif (Sudol, 2013; Sudol et al., 2012; Wang et al., 2014).
Of interest, these include the association of YAP with a cytoskel-
etal-associated protein, angiomotin (AMOT), which binds F-actin
through an N-terminal region that includes a sequence motif,
PPxY, by which AMOT associates with WW domains of YAP
(Oka et al., 2012; Chan et al., 2013; Dai et al., 2013). We reasoned
that F-actin may prevent AMOT’s associating with YAP and that
upon inhibition of actin polymerization, YAP may be sequestered
in an inactive, AMOT-associated pool. Preventing actin polymer-
ization in uveal melanoma cells did not enhance protein complex
formation between flag-tagged YAP and endogenous LATS or
14-3-3, both of which repress YAP function (Figure 5E). Instead,
YAP association with the endogenous p130 form of AMOT was
increased after inhibition of actin polymerization (Figure 5E).
This could be recapitulated in vitro, as AMOT bound to flag-YAP
was competed out by incubating the immunoprecipitates with
F-actin but not G-actin (Figure 5F). Consistently, AMOT knock-
down had limited impact on YAP-dependent gene expression in
uveal melanoma cells, as it is expected to bind YAP poorly inthe presence of cytosolic F-actin, but AMOT knockdown rescued
YAP function inhibition causedbyactin depolymerization (Figures
5G and 5H). Taken together, these findings suggest that in uveal
melanoma cells, F-actin accumulation causes the dissociation
of AMOT-YAP complexes, thereby contributing to YAP nuclear
translocation and YAP-dependent transcription (Figure 5I).
YAP Represents a Therapeutic Target in Uveal
Melanoma
We next explored the role of YAP activation in uveal melanoma
tumor formation. For these studies, we established lentiviral-
delivered small hairpin RNAs (shRNAs) knocking down YAP
and control shRNA in uveal melanoma cells. This approach re-
vealed that YAP knockdown resulted in reduced YAP-dependent
expression of typical YAP-regulated genes (Mo et al., 2012) and
decreased the proliferation of uveal melanoma cells (Figures
6A–6C). Furthermore, knockdown of YAP led to a reduced num-
ber of colonies in uveal melanoma cells cultured in 3D matrix, as
well as a reduced colony size (Figure 6D). Taking advantage of
the ability to establish uveal melanoma xenografts in immune
compromised mice, we observed that YAP knockdown reduced
tumor size in vivo (Figure 6E). Taken together, these results
suggest that YAP activation may represent a molecular event
involved in uveal melanoma tumor growth in vitro and in vivo.
These observations raised the possibility that YAP may repre-
sent a therapeutic target for the treatment of patients with uveal
melanoma. On the basis of the identification of verteporfin (VP)
as a potent inhibitor of the YAP-TEAD4 interaction in a recent
high-throughput drug screen (Liu-Chittenden et al., 2012), we
asked whether VP can exert an antitumoral activity in uveal mel-
anoma cell lines. VP treatment reduced colony formation and
proliferation of uveal melanoma cells in soft agar 3D cultures
(Figure 6F) and dramatically reduced uveal melanoma cell
tumorigenesis and proliferation in vivo (Figures 6G and 6H).
These results suggest that the pharmacological inhibition of
YAP by VP may represent as a therapeutic approach for the
treatment of patients with uveal melanomas.
DISCUSSION
Recent large cancer-sequencing efforts have revealed an unex-
pected high frequency of gain-of-function mutations in heterotri-
meric G protein a subunits (O’Hayre et al., 2013). Among them,
mutations in the GNAQ oncogenes, GNAQ and GNA11, are
now believed to represent the genetic initiating event in uveal
melanomas and in a subset of melanomas arising in the skin
(Van Raamsdonk et al., 2009; Van Raamsdonk et al., 2010),
among other tumors. In this study, we show that YAP activation
represents a key molecular event contributing toGNAQ-induced
tumorigenesis, which is dependent on the activation of Trio and
its regulated Rho GTPases, RhoA and Rac1, in uveal melanoma
cells harboring activating GNAQ mutations. Furthermore, we
provide evidence that YAP activation may involve, at least in
part, a Hippo-independent pathway impinging on the regulation
of the actin cytoskeleton by Rho GTPases. These findings sug-
gest that inhibition of YAP function may represent a suitable
pharmacological intervention strategy in uveal melanoma and
other hyperproliferative lesions that result from gain-of-function
GNAQ mutations.Cancer Cell 25, 831–845, June 16, 2014 ª2014 Elsevier Inc. 837
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GNAQ Drives Uveal Melanoma Growth through YAPYAP is a transcriptional coactivator that acts as a powerful tu-
mor promoter, and its activation is a frequent event in numerous
cancers, including lung, colorectal, ovarian, liver, and prostate
cancers (Dong et al., 2007; Johnson and Halder, 2014; Zhao
et al., 2007). The Hippo pathway is believed to be the major
regulator of YAP nuclear localization, activity, and tumorigenic
potential (Camargo et al., 2007; Dong et al., 2007; Pan, 2010;
Ramos and Camargo, 2012; Zhao et al., 2010). YAP and its
D. melanogaster counterpart Yorkie (YKI) promote tissue growth
and cell viability by regulating the activity of different transcrip-
tion factors, including TEADs and SMADs. In mammals, YAP
overexpression or hyperactivation causes excess proliferation
in multiple tissues, including the liver, gastrointestinal tract,
skin, and heart (Camargo et al., 2007; Dong et al., 2007; Schle-
gelmilch et al., 2011). Despite this, somatic or germline muta-
tions in Hippo pathway genes are uncommon, prompting the
exploration of other mechanism(s) underlying YAP activation in
each tumor type (Johnson and Halder, 2014).
Recent studies suggest that G protein-coupled receptor
(GPCR) signaling can regulate the Hippo pathway (Yu et al.,
2012). Specifically, GPCRs linked to Ga12/13 inhibit the activity
of LATS, thereby relieving YAP from the LATS-dependent inhibi-
tory phosphorylation in serine 127 (Yu et al., 2012), while recep-
tors activating Gas may promote LATS activation, thus causing
YAP inhibition by increasing Hippo pathway activation. Whether
GNAQ-activating mutations and the large family of receptors
regulating cell growth through Gaq affect the Hippo pathway,
however, is much less understood (Yu et al., 2012). In our study,
we found that YAP is a key protumorigenic gene in uveal mela-
nomacells harboringGNAQactivatingmutations,which is critical
for uveal melanoma growth and tumor formation as judged by
knockdown experiments and by the use of small-molecule
inhibitors. Moreover, we also showed that activation of YAP
downstream of Gaq occurs through the stimulation of Trio and
Trio-dependent-Rho GTPases, RhoA and Rac1. Of interest,
Gaq activation did not result in decreased levels of phosphory-
lated LATS and YAP, and Gaq activated YAP further even when
LATS was knocked down in both uveal melanoma and HEK293Figure 4. GNAQ Oncogenic Signaling Induces YAP Nuclear Translo
GTPases and Actin Remodeling
(A) Western blots show expression of total and phosphorylated (serine 127) YA
expressing BRAF and NRAS oncogenes, as indicated, as well as in HEK293 cell
(B and C) Cell lysates were subjected to immunoblotting with the indicated ant
status. Dephosphorylated YAP was reflected by the faster migration of YAP. (B) P
YAP in the cytosolic (Cyt.) and nuclear (Nucleus) fractions of HEK293 cells trans
forms) in uveal and cutaneous melanoma cells expressing the indicated oncoge
(D) HEK293 cells were cotransfected with siRNA LATS1 and LATS2 or control and
HA-Gaq, LATS1, LATS2, p(127)-YAP, YAP, and a tubulin as a loading control.
(E) Similarly, cells were also transfected with Gal4-TEAD4, 5 3 UAS-Luc, and Re
(F) Cells were also studied by qPCR to assess the expression levels of YAP-regu
(G) Levels of cofilin and p-cofilin in HEK293 cells expressing GaqQL or vector co
(H) Accumulation of phosphorylated cofilin in HEK293 cells expressing RhoAQL
(I) Expression of YAP-regulated genes (CTGF and CYR61) in HEK293 cells expre
(J) OMM1.3 uveal melanoma cells treated with Y-27632 or Lat.A, following with im
phalloidin stains F-actin (violet).
(K) Proportion of cells displaying preferential nuclear (N), nuclear and cytoplasm
(L) Y-27632 or Lat.A treatments were followed by western blot analysis for p-cofi
(M) Impact of Y-27632 and Lat.A treatments on the expression of endogenou
melanoma cells (mean ± SEM, n = 3).
See also Figure S3.cells. Instead, our results suggest that Gaq stimulates YAP by a
process involving changes in actin dynamics rather than solely
by Hippo kinase cascade regulation, resembling recent findings
in the context of mechanosensing transduction signals (Aragona
et al., 2013; Dupont et al., 2011; Halder et al., 2012).
In this regard, whereas in Drosophila, most of the key compo-
nents of the Hippo pathway have been genetically defined, in
mammalian cells, YAP may receive negative and positive inputs
from multiple signaling systems in addition to those described in
flies. For example, a recent kinome-wide screen in mammalian
cells revealed that the tumor suppressor protein LKB1 inhibits
YAP by activating the core Hippo kinases, while members of
the c-Jun N-terminal kinase pathway diminish YAP function
independently of Hippo (Mohseni et al., 2014). The regulation
of YAP by the cytoskeleton in Drosophila involves the tumor
suppressor Merlin/NF2, which can cause the activation of
Drosophila LATS (Wts) and hence activate the Hippo pathway,
diminishing Yki activity upon the disruption of the cytoskeleton
(Yin et al., 2013). Although this repressive function is also likely
performed by NF2 in mammals, the activation of YAP by mecha-
nosensing mechanisms appears not to require LATS inhibition,
as supported by multiple experimental approaches (Aragona
et al., 2013; Dupont et al., 2011). Similarly, active Gaq, RhoA,
and Rac1 stimulated YAP potently even when endogenous
LATS1/2 were efficiently knocked down. In line with this possibil-
ity, in uveal melanoma cells, LATS1 is phosphorylated in its acti-
vation loop, while LATS1/2 knockdown results in a remarkable
increase in the transcriptional activity of YAP, indicating that
these core Hippo kinases retain a restraining activity on YAP
function. Instead, disruption of the actin cytoskeleton diminishes
both the basal activity of YAP and YAP hyperactivation caused
by LATS1/2 reduced expression. Thus, YAP stimulation by
GNAQ in uveal melanoma cells requires the persistent activation
of a cytoskeleton-regulated pathway, which may cooperate with
or bypass the requirement of Hippo pathway inactivation.
The fact that RhoA and Rac1 stimulate YAP, albeit RhoA more
potently, may provide some possible hints on the underlying
mechanism. Although these GTPases often act antagonisticallycation and YAP-Dependent Transcription Activation through Rho-
P and LATS1 and LATS2 in uveal and cutaneous melanoma cells, the latter
s expressing GaqQL or vector (v) as controls.
ibodies. Gels containing phos-tag were used to assess YAP phosphorylation
hosphorylated YAP (p-YAP and slower mobility forms) and dephosphorylated
fected with GaqQL or vector control. (C) Phosphorylated YAP (slower mobility
nes.
HA-GaqQL or vector DNAs, followed by the indicated western blot analysis for
nilla-Luc DNAs, followed by luciferase assay (mean ± SEM, n = 3).
lated genes (CTGF and CYR61) (mean ± SEM, n = 3).
ntrol, as well as in the indicated uveal and cutaneous melanoma cells.
or Rac1QL.
ssing RhoAQL or Rac1QL (mean ± SEM, n = 3).
munofluorescence assay, YAP (green), Hoechst stains nuclear DNA (blue), and
ic (N/C), or cytoplasmic (C) YAP location (left panel; n = 50–100 cells).
lin, cofilin, p127-YAP, YAP, and a tubulin as a loading control.
s YAP-regulated genes (CTGF and CYR61) in OMM1.3 and OMM1.5 uveal
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Figure 5. Actin Remodeling Results in Hippo-Independent Activation of YAP Downstream of GNAQ Oncogenic Signaling
(A) OMM1.3 and OMM1.5 cells were transfected with siRNAs for LATS1 and LATS2 and treated with control diluent or Y-27632 and Lat.A, followed by western
blot analysis for LATS1, LATS2, p-cofilin, cofilin, p127-YAP, YAP, and a tubulin as a loading control.
(B) Similarly, cells were also followed by qPCR to analyze the expression of YAP-regulated genes (CTGF and CYR61) (mean ± SEM, n = 3).
(C) HEK293 cells were cotransfected with siRNA, LATS1 and LATS2, and HA-GaqQL and treated with Y-27632 or Lat.A, followed by the indicated western blot
analysis for HA-GaqQL, LATS1, LATS2, p-cofilin, cofilin, p127-YAP, YAP, and a tubulin as a loading control.
(D) Cells were also followed by qPCR to assess the expression levels of YAP-regulated genes (CTGF and CYR61) (mean ± SEM, n = 3).
(E) OMM1.3 cells expressing flag-tagged YAP treatedwith Lat.A or control were lysed and followed by antiflag and control (immunoglobulin G) IP andwestern blot
analysis for flag-YAP, AMOT, LATS1, and 14-3-3 present in the immuneprecipitates, using the input lysate as control.
(F) Antiflag immunoprecipitates from HEK293 cells expressing flag-YAP were exposed to G-actin or F-actin, washed, and analyzed by western blot for flag-YAP
and associated endogenous AMOT.
(G) OMM1.3 cells were transfected with siRNA for AMOT, followed by the indicated western blot analysis for AMOT (recognizing both p130 and p80 forms) and a
tubulin as a loading control.
(H) OMM1.3 cells were transfected with siRNA AMOT or siRNA control, followed by Lat.A treatment or control, and the expression of YAP-regulated genes
(CTGF and CYR61) was determined by qPCR.
(legend continued on next page)
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GNAQ Drives Uveal Melanoma Growth through YAPfor cell movement, they both converge in the activation of LIMK
and the consequent phosphorylation and inactivation of the
actin-severing protein cofilin, thus favoring actin polymerization
and F-actin accumulation (reviewed in Bar-Sagi and Hall,
2000). RhoA activates LIMK through ROCK, and Rac1 stimulates
this kinase through PAK (reviewed in Bar-Sagi and Hall, 2000;
Radu et al., 2014), which can explain why ROCK inhibitors
do not prevent the activation of YAP by the latter. In turn, how
F-actin stimulates YAP was unclear (reviewed in Matsui and
Lai, 2013). YAP is part of multiple cytosolic protein complexes,
many of which are driven by the direct interaction between the
WW domains of YAP with the PPxY motifs present in most
of its associated proteins, including LATS and AMOT (Sudol,
2013; Sudol et al., 2012; Wang et al., 2014). The latter has
recently received increased attention, as AMOT represses YAP
function (Chan et al., 2011; Zhao et al., 2011) and competes
for LATS binding to YAP (Yi et al., 2013), while there are no
AMOT orthologs in Drosophila, thus representing a fundamental
difference in Hippo signaling between Drosophila and verte-
brates (Bossuyt et al., 2014). Our present findings are consistent
with a model in which AMOT retains YAP in a complex that is
protected from LATS inhibition, but this AMOT-bound pool of
YAP can then be mobilized by F-actin, promoting the release
of YAP and its subsequent nuclear accumulation, resulting
in increased transcription of its target genes (Figure 5I). In turn,
this potential mechanism of YAP regulation may explain the still
poorly understood mechanosensing role of YAP and some
seemingly contradictory results regarding AMOT function, as
AMOT may act as a YAP inhibitor or facilitate YAP activation
depending on the status of actin polymerization. These possibil-
ities, as well as how the interplay between AMOT and LATS
and the actin cytoskeleton (Adler et al., 2013; Chan et al.,
2013; Dai et al., 2013; Hong, 2013; Paramasivam et al.,
2011; Yi et al., 2013) regulates YAP, will surely warrant further
investigation.
A high rate of mutations in GPCRs and G proteins has been
recently identified in melanoma (Kan et al., 2010; O’Hayre et al.,
2013; Prickett et al., 2011). Strikingly, mutations in GNAQ and
GNA11 have been observed in the majority of uveal melanomas,
83% of blue nevi, 6% of cutaneous melanomas, and 59% of
tumors arising in the meninges (Ku¨sters-Vandevelde et al.,
2010; Van Raamsdonk et al., 2009). Somatic mosaic mutations
in GNAQ have been also recently identified in port-wine stains
in infants and as the genetic alteration underlying Sturge-Weber
syndrome (Shirley et al., 2013), while GNA11 gain-of-function
mutations cause autosomal-dominant hypocalcemia (Nesbit
et al., 2013). The growth-promoting potential of GNAQ mutants
requires theactivation of a complex signaling network stimulating
the expression of AP-1-regulated genes (Vaque´ et al., 2013).(I) Schematic representation of Hippo-dependent and Hippo-independent pathwa
protein stimulates YAP through a RhoA and Rac1 regulated signaling circuitry i
pendently of the best-known stimulation of secondmessengers through PLCb. In
in the activation of LIMK that phosphorylates and inactivates the actin-severing
depicted for simplicity, dotted line). F-actin may then bind AMOT, displacing YAP,
also bind to LATS, which phosphorylates and inactivates YAP upon the cytosol
teosomal degradation (the latter not depicted), as part of a canonical Hippo-dep
function is not fully understood (dotted line). It is expected that in the presence ofG
likely dominant F-actin-mediated stimulation of YAP to promote YAP stabilizat
regulated growth-promoting genes. See text for details.However, this signaling route may not yet be suitable for cancer
treatment. Here, we show that activation of YAP represents a
key molecular event downstream of GNAQ and GNA11 in uveal
melanoma.Moreover, recent efforts have exposed YAPas a suit-
able therapeutic target (Sudol et al., 2012). Liu-Chittenden et al.
(2012) screened a small-molecule library for compounds inhibit-
ing the transcriptional activity of YAP in vitro. Among them, VP, a
benzoporphyrin derivative, is in clinical useasaphotosensitizer in
photocoagulation therapy for patients with wet age-related
macular degeneration (Michels and Schmidt-Erfurth, 2001).
Both YAP knockdown and VP treatment reduce uveal melanoma
cell growth in vitro and tumor formation in vivo. In light of our ob-
servations, the successful use of photodynamic therapy (PDT)
using VP as a photosensitizer for the treatment of some patients
with posterior uveal melanomas (Barbazetto et al., 2003; Soucek
and Cihelkova, 2006) is very intriguing. It is presumed that the
mechanism of action of PDT for uveal melanoma is damage
to the tumor vasculature, but the pharmacological inhibition of
YAP by VP may provide an unexpected alternative explanation
for its therapeutic success in some patients. Indeed, although it
is unclear whether VP may be also active in cancers driven by
other tumor-promoting genes, we can postulate that the tran-
scriptional coactivator YAPmay represent a suitable therapeutic
target for the treatment of uveal melanoma and other human dis-
eases that result from gain-of-function mutations in the GNAQ
and GNA11 oncogenes.
EXPERIMENTAL PROCEDURES
Cell Lines, Culture Procedures, and Chemicals
Uveal melanoma OMM1.3, OMM1.5, Mel270, and 92.1 cells and cutaneous
melanoma WM-266 and SK-mel-2 cells have been described elsewhere
(Schmitt et al., 2007; Zuidervaart et al., 2005). Cells knocked down for Trio
and YAP and their corresponding controls were generated as described in
Supplemental Experimental Procedures. Y-27632 (Tocris Cookson) (10 mM)
and Lat.A (Tocris Cookson) (1 mM) were used to treat uveal melanoma cells
for 1 or 6 h, followed by immunofluorescence, western blot analysis and immu-
noprecipitation (IP) or quantitative PCR (qPCR), respectively. VP (Chemical
Abstracts Service No. 129497-78-5; USP Reference Standards) was prepared
as a stock solution in DMSO. See Supplemental Experimental Procedures.
Small Interfering RNA and DNA Constructs
All human small interfering RNA (siRNA) sequences and providers, as well as
DNA constructs, are described in Supplemental Experimental Procedures.
Statistical Analysis
All data analysis was performed using GraphPad Prism version 6 for Windows
(GraphPad Software). The data were analyzed using ANOVA or t tests.
Animal Studies
All animal studies were approved by the Animal Care and Use Committee,
National Institute of Dental and Craniofacial Research, in compliance withys resulting in YAP activation by theGNAQ oncogene in uveal melanoma. Gaq
nitiated by the activation of Trio, a Rho-GEF activating these GTPases, inde-
turn, RhoA activates ROCK and Rac1 stimulates PAK proteins, which converge
protein cofilin, resulting in actin polymerization and F-actin accumulation (not
which translocates to the nucleus and initiates gene expression. Free YAP can
ic sequestration of phospho-YAP by 14-3-3 proteins or by promoting its pro-
endent pathway restraining YAP function. How Rho GTPases regulate LATS
NAQ oncogenes, LATS reduced activity acts in a coordinated function with the
ion and nuclear translocation, ultimately resulting in the expression of YAP-
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Figure 6. YAP Represents a Therapeutic Target in Uveal Melanoma
(A) Western blot shows YAP knockdown by doxycycline-inducible shRNAs (YAP#1 and YAP#2) in OMM1.3 uveal melanoma cells.
(B) Impact of shRNAs knocking down YAP on the expression of endogenous YAP-regulated genes (CTGF and CYR61) in OMM1.3 uveal melanoma cells
(mean ± SEM, n = 5).
(C) Effect of shRNA knock down of YAP in OMM1.3 uveal melanoma cell proliferation (mean ± SEM, n = 3).
(D) OMM1.3 uveal melanoma cell colony formation in soft agar after shRNA-mediated knockdown of YAP. shRNA positive cells (control and YAP#1 and YAP#2)
expressed Tomato (red) (left panel), nd were counted (right upper panel) (mean ± SEM, n = 10) and their size measured (right lower panel) with ImageJ
(mean ± SEM, n = 20–100 colonies).
(E) OMM1.3 uveal melanoma formation in vivo in cells expressing control and YAP shRNAs. Tumor size at the end of the studywasmeasured (mean ± SEM, n = 6)
(upper panel); hematoxylin and eosin (H&E)-stained sections of representative tumors from each group are shown (lower panel).
(F) Soft agar assays show the effect of VP treatment on OMM1.3 uveal melanoma cell colony formation ability (left panel) and colony size (mean ± SEM, n = 20–50
colonies) (right panel).
(legend continued on next page)
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GNAQ Drives Uveal Melanoma Growth through YAPthe Guide for the Care and Use of Laboratory Animals. Animals were housed
on 12-h light/dark cycles and received food, standard rodent chow, and water
ad libitum in compliance with Association for Assessment and Accreditation of
Laboratory Animal Care International guidelines. See also Supplemental
Experimental Procedures.
Human Tumor Xenografts and In Vivo Treatment with VP
Female NOD.Cg-Prkdcscid Il2rgtm1wjl/SzJ mice 5 to 6 weeks of age weighing
18 to 20 g were used in the study of tumor formation essentially as previously
described (Vaque´ et al., 2013). The animals were monitored twice weekly
for tumor development. Results of animal experiments were expressed as
mean ± SEM of a total of six tumors analyzed. See Supplemental Experimental
Procedures for technical details and a description of the treatment with VP
(Liu-Chittenden et al., 2012).
Small GTPase Activation, Immunobloting, and Phosphoinositide
Turnover Assays
RhoA and Rac1 activity was assessed using a modified method described
previously (Vaque´ et al., 2013). Western blots and phosphoinositide (PI) turn-
over assays were performed as described previously (Vaque´ et al., 2013).
See Supplemental Experimental Procedures for antibody information and
technical details.
IP and YAP-Protein Complex Interaction and Competition Assays
See Supplemental Experimental Procedures.
Clinical Samples
Snap-frozen uveal melanoma tissues were generously provided by Dr. James
T. Handa and Dr. Shannath Merbs, Wilmer Eye Institute, Johns Hopkins
School of Medicine; tissue was obtained from consenting patients in accor-
dance with a study approved by the Institutional Review Board at the Johns
Hopkins School of Medicine. Normal skin samples were purchased from US
Biomax and Biochain.
Immunofluorescence
See Supplemental Experimental Procedures.
Luciferase Assays
HEK293 cells were cotransfected with TEAD4-Gal4 (0.5 mg/ml), Gal4-luc
(0.5 mg/ml), and pRLNull (1 mg/ml) in 24-well plates overnight to the detection
of the luciferase activity, using a Dual-Glo Luciferase Assay Kit (Promega) and
a Microtiter plate luminometer (Dynex Technologies).
Immunohistochemistry
See Supplemental Experimental Procedures.
Growth in Soft Agar
Cells were mixed at a concentration of 2,500 cells/0.2 ml of medium, and 0.2%
agar (Lonza). The cells in 0.2% agar were plated over 0.2 ml of medium, 1%
agar that had been allowed to harden in a 96-well dish. Cells were fed 50 ml
of medium every 4 days. In the VP treatment assay, VP was added in the
medium with a final concentration of 1 mM.
Nuclear and Cytoplasm Extraction
Follow the instructions of NE-PER Nuclear and Cytoplasmic Extraction
Reagents (Thermo Fisher Scientific).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and three figures and can be found with this article online at http://dx.doi.
org/10.1016/j.ccr.2014.04.016.(G) Effect of VP on OMM1.3 uveal melanoma cell growth in vivo. Tumor size w
(mean ± SEM, n = 6; n = number of tumors analyzed) (left panel). H&E-stained se
(H) Effect of VP treatment on OMM1.3 uveal melanoma cell proliferation in the tu
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